BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...
BC Innovations | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies identified an aryloxytetramethylcyclobutane-based degrader of androgen receptor that could help treat prostate cancer. Chemical synthesis and testing in three prostate cancer cells lines of analogs of a...
BC Innovations | May 30, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro , cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling...
BC Innovations | Jul 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified a compound that recruits androgen receptor to IAP for proteasomal degradation that could help treat prostate cancer. The compound consisted of an androgen receptor ligand and a peptidomimetic...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Androgen receptor

Cancer INDICATION: Prostate cancer Cell culture and mouse studies identified a peptoid-based androgen receptor antagonist that could help treat prostate cancers resistant to Xtandi enzalutamide and other androgen receptor antagonists. In multiple human prostate cancer...
BC Extra | Apr 30, 2016
Top Story

Medivation rejects Sanofi bid

To little surprise, Medivation Inc. (NASDAQ:MDVN) rejected an unsolicited bid from Sanofi (Euronext:SAN; NYSE:SNY) to acquire the company for $52.50 per share in cash, or about $9.3 billion. Sanofi made its offer public on Thursday...
BC Week In Review | Apr 25, 2016
Clinical News

Xtandi enzalutamide regulatory update

Medivation and Astellas said EMA’s CHMP recommended approval of a Type II variation for Xtandi enzalutamide to update the label to include Phase II data comparing Xtandi vs. Casodex bicalutamide in patients with metastatic castration-resistant...
BC Week In Review | Mar 7, 2016
Clinical News

Xtandi enzalutamide regulatory update

Astellas and Medivation said FDA accepted for review an sNDA for Xtandi enzalutamide to update the label to include Phase II data comparing Xtandi vs. Casodex bicalutamide in patients with metastatic castration-resistant prostate cancer (CRPC)....
BC Innovations | Dec 10, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-124 (miR-124)

Cancer INDICATION: Prostate cancer Mouse studies suggest miR-124 could help treat castration-resistant prostate cancer (CRPC). In human prostate cancer cell lines, miR-124 plus Xtandi enzalutamide or Casodex bicalutamide decreased proliferation compared with either agent alone....
BC Week In Review | Apr 13, 2015
Clinical News

Xtandi enzalutamide: Phase II data

Top-line data from the double-blind, U.S. Phase II STRIVE trial in 396 patients with CRPC showed that once-daily 160 mg oral Xtandi met the primary endpoint of improving median PFS vs. once-daily 50 mg oral...
Items per page:
1 - 10 of 50